<DOC>
	<DOCNO>NCT01060202</DOCNO>
	<brief_summary>This study observe degree quality life non-transplant candidate patient multiple myeloma bortezomib administration use EORTC-QLQ C30 ( European Organization Research Treatment Cancer Quality Life Questionnaire-Core30 ) EQ-5D ( EuroQol-5 Dimensions ) . Both tool validate research instrument use measure quality life cancer patient consequently provide fundamental data regard quality life patient multiple myeloma analyze factor affect quality life .</brief_summary>
	<brief_title>Quality Life Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib</brief_title>
	<detailed_description>Multiple myeloma ( MM ) plasma cell malignancy progression mark symptom sign lower resistance infection , skeletal destruction , renal failure , anemia . It incurable follow relapse course , median survival approximately 4-5 year . The various therapy associate disease control , often associate significant side effect , ultimately , patient relapse . Therefore , assessment health-related quality life ( HRQL ) represent important tool evaluate value effective therapy weigh potential toxic effect treatment patient 's perspective . Patients diagnose MM suffer pain , fatigue , reduce physical role functioning , reduce overall HRQL compare age- gender-matched population . These symptom improve successful treatment either cytotoxic therapy supportive care . Many clinical study treatment multiple myeloma conduct Korea , none evaluate improvement quality life patient multiple myeloma . Most study variable use evaluate quality life patient multiple myeloma subjective limit . This study observe degree quality life patient early status multiple myeloma bortezomib administration use EORTC-C30 ( European Organization Research Treatment Cancer Quality Life Questionnaire-Core30 ) EQ-5D ( EuroQol-5 Dimensions ) , validate research instrument use measure quality life cancer patient consequently provide fundamental data regard quality life patient multiple myeloma . Observational Study - No investigational drug administer .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Symptomatic multiple myeloma patient ECOG score le 3 Patient candidate stem cell transplantation Previous treatment duration le 6 month Previous treatment response less partial response ( PR ) Willing able complete questionnaire Patients ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Known hypersensitivity bortezomib Acute severe infection require antibiotic therapy Preexisting peripheral neuropathy great equal grade 2 Uncontrolled severe cardiovascular disease Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>QoL</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>EORTC QLQ C30</keyword>
	<keyword>EQ 5D</keyword>
</DOC>